In particular, galectin-3 has remained the central protein in the midst of inhibitor discovery, as its overexpression has been associated with cancer drug resistance (9, 10), and hence it has been identified as a valuable therapeutic target in the fight against cancers (11). The gene discussed is LGALS3; the disease is cancer.